Fuzapladib Sodium CAS 141283-73-3 GMP Anti-Inflammatory Series

Fuzapladib Sodium CAS 141283-73-3 GMP Anti-Inflammatory Series. GMP Manufacturing: Produced under strict GMP conditions ensuring safety, stability, and traceability. Anti-Inflammatory Mechanism: Selective inhibitor of LFA-1 activation and phospholipase A2 for blocking inflammation. Comprehensive CDMO Services: One-stop solutions covering process development, pilot scale-up, and commercial production. Strong R&D Capability: High-level team with National Postdoctoral Research Station and multiple technology platforms. Strict Quality Control: Passed 6 consecutive US FDA inspections and 4 domestic GMP inspections. Flexible Customization: Customization options available based on customer samples.